Last reviewed · How we verify
NCT07112612
Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
trial in MRD in 50 participants. Not yet recruiting.
30 December 2026
Quick facts
| Lead sponsor | Anhui Medical University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 30 January 2026 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 April 2027 |
Conditions studied
- MRD — all drugs for MRD →
- Prostate Cancer — all drugs for Prostate Cancer →
- mHSPC — all drugs for mHSPC →
Sponsor
Anhui Medical University
Who can join
Adults 18 to 85, male only, with MRD or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Minimal residual disease (MRD) detection is used to investigate the actual efficacy responses of mHSPC patients with different gene mutation characteristics to treatment regimens. Factors influencing efficacy are further analyzed to provide a basis for the precise clinical diagnosis and treatment of mHSPC patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07112612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MRD
Currently open trials in the same condition.
- NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
- NCT06409702 — Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection · Phase 4 · recruiting
- NCT06918262 — Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer · recruiting
- NCT05736978 — Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results · Phase 2 · recruiting
- NCT05536505 — Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC · Phase 2 · recruiting
Other Anhui Medical University trials
Trials by the same sponsor.
- NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
- NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
- NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
- NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting
- NCT07330648 — Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07112612 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
- Last refreshed: 12 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07112612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing